Investigation Launched into Soleno Therapeutics' Deal with Neurocrine: Are Shareholders Being Shortchanged? Ademi LLP is probing Soleno Therapeutics over potential violations in its agreement with Neurocrine that may not benefit public shareholders adequately.

Investigation Launched into Soleno Therapeutics' Deal with Neurocrine: Are Shareholders Being Shortchanged? #United_States #Milwaukee #Neurocrine #Ademi_LLP #Soleno_Therapeutics

Neurocrine Nears $2.5B Deal for Soleno Neurocrine reportedly close to buying Soleno for $2.5B+ (FT, Apr 6, 2026); deal structure and milestone split will determine ultimate value and timing.

Neurocrine Nears $2.5B Deal for Soleno: Neurocrine reportedly close to buying Soleno for $2.5B+ (FT, Apr 6, 2026); deal structure and milestone split will determine ultimate value and timing. 👈 Read full analysis #Neurocrine #Soleno #BusinessNews #MergersAndAcquisitions #HealthcareInvesting

Neurocrine Nears $2.5bn Deal for Soleno Neurocrine is reportedly in talks to buy Soleno for >$2.5bn (FT Apr 6, 2026). Soleno sells the first commercial therapy for hyperphagia in Prader-Willi syndrome.

Neurocrine Nears $2.5bn Deal for Soleno: Neurocrine is reportedly in talks to buy Soleno for >$2.5bn (FT Apr 6, 2026). Soleno sells the first commercial therapy for hyperphagia in Prader-Willi syndrome. 👈 Read full analysis #Neurocrine #Soleno #Pharmaceuticals #Acquisition #Healthcare

Neurocrine Biosciences Schedules 2025 R&D Day Event in December Neurocrine Biosciences is set to host its 2025 R&D Day on December 16 to discuss its evolving neuroscience pipeline and transformation efforts, featuring expert insights.

Neurocrine Biosciences Schedules 2025 R&D Day Event in December #Neurocrine #Neuroscience #R&D_Day

Neurocrine Biosciences Reveals Efficacy of INGREZZA® in New Findings A recent analysis highlights the sustained therapeutic benefits of INGREZZA® in treating tardive dyskinesia, showing promising results for patients over a 48-week treatment period.

Neurocrine Biosciences Reveals Efficacy of INGREZZA® in New Findings #Neurocrine #INGREZZA #Tardive_Dyskinesia

Neurocrine Biosciences Unveils Promising Data on INGREZZA's Impact on Tardive Dyskinesia Remission Rates New insights from Neurocrine Biosciences reveal that INGREZZA capsules lead to faster remission of tardive dyskinesia symptoms, highlighting significant patient-reported benefits.

Neurocrine Biosciences Unveils Promising Data on INGREZZA's Impact on Tardive Dyskinesia Remission Rates #USA #San_Diego #Neurocrine #INGREZZA #Tardive_Dyskinesia

Promising Results from Neurocrine Biosciences' Phase 2 Study of Osavampator for Major Depression Neurocrine Biosciences shares positive Phase 2 trial results for osavampator, highlighting significant improvement in patients with major depressive disorder.

Promising Results from Neurocrine Biosciences' Phase 2 Study of Osavampator for Major Depression #United_States #San_Diego #Depression #Neurocrine #Osavampator

Neurocrine Biosciences Reveals Promising One-Year Data on CRENESSITY for CAH at ENDO 2025 Neurocrine Biosciences presented compelling one-year data on CRENESSITY at ENDO 2025, showcasing sustained efficacy in treating adults with congenital adrenal hyperplasia.

Neurocrine Biosciences Reveals Promising One-Year Data on CRENESSITY for CAH at ENDO 2025 #USA #San_Francisco #Crenessity #CAH #Neurocrine

Significant Quality of Life Improvements with INGREZZA in Older Adults with Tardive Dyskinesia Neurocrine Biosciences reveals new findings, showcasing the positive impact of INGREZZA on health-related quality of life for older adults dealing with tardive dyskinesia.

Significant Quality of Life Improvements with INGREZZA in Older Adults with Tardive Dyskinesia #USA #San_Diego #Neurocrine #INGREZZA #Tardive_Dyskinesia

Neurocrine Biosciences Unveils Promising KINECT-PRO Study Results on INGREZZA for Tardive Dyskinesia Neurocrine Biosciences presents insights from the KINECT-PRO study, showcasing significant patient-reported improvements in functionality and quality of life for those with tardive dyskinesia using INGREZZA.

Neurocrine Biosciences Unveils Promising KINECT-PRO Study Results on INGREZZA for Tardive Dyskinesia #USA #San_Diego #Neurocrine #INGREZZA #Tardive_Dyskinesia

Insights from Neurocrine Biosciences on High-Dose Glucocorticoid Effects in Congenital Adrenal Hyperplasia Neurocrine Biosciences sheds light on how high doses of glucocorticoids affect clinical outcomes in patients with congenital adrenal hyperplasia during ISPOR 2025.

Insights from Neurocrine Biosciences on High-Dose Glucocorticoid Effects in Congenital Adrenal Hyperplasia #United_States #San_Diego #Neurocrine #Congenital_Adrenal_Hyperplasia #Glucocorticoids

Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer Neurocrine Biosciences appoints Dr. Sanjay Keswani as CMO, bringing over two decades of RD expertise to strengthen their leadership.

Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer #USA #San_Diego #CMO #Neurocrine #Sanjay_Keswani

Neurocrine Biosciences Reveals Insights on VMAT2 Inhibitors in Tardive Dyskinesia Treatment Neurocrine Biosciences showcases real-world data confirming that all patients using INGREZZA achieve therapeutic doses unlike deutetrabenazine. Key findings will be shared at the upcoming pharmacy meeting.

Neurocrine Biosciences Reveals Insights on VMAT2 Inhibitors in Tardive Dyskinesia Treatment #United_States #Houston #Neurocrine #INGREZZA #VMAT2_Inhibitors

Neurocrine Biosciences Unveils Promising 48-Week Remission Results for Tardive Dyskinesia with INGREZZA Neurocrine Biosciences shared new data showing significant remission rates in tardive dyskinesia patients using INGREZZA, underscoring its effectiveness in treatment.

Neurocrine Biosciences Unveils Promising 48-Week Remission Results for Tardive Dyskinesia with INGREZZA #USA #Chicago #Neurocrine #INGREZZA #Tardive_Dyskinesia

Neurocrine Biosciences to Showcase Innovations at March Investor Conferences In March, Neurocrine Biosciences will participate in significant investor conferences, led by its CEO and financial leaders, showcasing its innovative therapies for neurological disorders.

Neurocrine Biosciences to Showcase Innovations at March Investor Conferences #United_States #Boston #Investor #Neurocrine #Biosciences

Neurocrine Biosciences Unveils $500 Million Share Buyback Initiative to Boost Investor Confidence Neurocrine Biosciences has authorized a $500 million share repurchase program. This move is intended to enhance shareholder value while supporting growth strategies.

Neurocrine Biosciences Unveils $500 Million Share Buyback Initiative to Boost Investor Confidence #United_States #San_Diego #share_repurchase #Neurocrine #INGREZZA

Neurocrine Biosciences Launches Phase 3 Study for Osavampator to Combat Major Depressive Disorder Neurocrine Biosciences has initiated a Phase 3 study for osavampator as an adjunctive therapy for major depressive disorder, aiming to help millions affected by this debilitating condition.

Neurocrine Biosciences Launches Phase 3 Study for Osavampator to Combat Major Depressive Disorder #United_States #San_Diego #Neurocrine #Osavampator #Biosciences

Neurocrine Biosciences Enhances Collaboration with Takeda for Osavampator Development Neurocrine Biosciences has amended its agreement with Takeda, granting it global rights for osavampator development outside Japan, including Phase 3 trials.

Neurocrine Biosciences Enhances Collaboration with Takeda for Osavampator Development #United_States #San_Diego #Neurocrine #Takeda #Osavampator

Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D. as Senior Vice President Neurocrine Biosciences announces the appointment of Andrew Ratz, Ph.D., as Senior Vice President, Drug Development and Delivery, enhancing its expanding R&D initiatives.

Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D. as Senior Vice President #United_States #San_Diego #Drug_Development #Neurocrine #Andrew_Ratz

Neurocrine Biosciences Introduces Innovative Treatment for Congenital Adrenal Hyperplasia Neurocrine Biosciences has published a significant review on CAH treatment challenges, proposing novel therapies minimizing glucocorticoid.use.

Neurocrine Biosciences Introduces Innovative Treatment for Congenital Adrenal Hyperplasia #United_States #San_Diego #Crenessity #CAH #Neurocrine

PANTHERx® Rare Selected for Distribution of Crenessity™ by Neurocrine Biosciences, Transforming CAH Treatment Neurocrine Biosciences has chosen PANTHERx® Rare for distributing Crenessity™, an innovative treatment for congenital adrenal hyperplasia affecting many lives.

PANTHERx® Rare Selected for Distribution of Crenessity™ by Neurocrine Biosciences, Transforming CAH Treatment #United_States #Pittsburgh #PANTHERx #Crenessity #Neurocrine

Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S. Neurocrine Biosciences has launched CRENESSITY™, a groundbreaking treatment for classic congenital adrenal hyperplasia (CAH), now available in the U.S. for eligible patients.

Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S. #United_States #San_Diego #Crenessity #CAH #Neurocrine